Ambrisentan: a guide to its use in pulmonary arterial hypertension in the EU


    loading  Checking for direct PDF access through Ovid

Abstract

Ambrisentan [Volibris® (EU), Letairis® (USA)] is an effective and well-tolerated first-line option for the treatment of adults with pulmonary arterial hypertension (PAH) classified as WHO functional class II or III. Ambrisentan provides sustained improvements in exercise capacity and dyspnoea, stabilizes WHO functional class, increases time to clinical worsening, and has an acceptable tolerability and safety profile. Ambrisentan is associated with fewer drug interactions than other available endothelin-1 receptor antagonists, may be used concomitantly with other common PAH medications, is associated with a low risk of liver function abnormalities, and has a convenient once-daily oral administration regimen.

    loading  Loading Related Articles